Vedolizumab (Entyvio) and ustekinumab (Stelara) appear to be equally effective for extraintestinal manifestation (EIM) of inflammatory bowel disease (IBD), according to results of a retrospective ...
Up to 40% of IBD patients may experience EIMs, with higher risks in Crohn disease and specific disease locations. Five key risk factors for EIMs include disease type, sex, ocular manifestations, ...
Certain extraintestinal manifestations (EIMs) in inflammatory bowel disease (IBD) have distinct clinical, serologic, and genetic associations that reveal underlying mechanisms and indicate targets for ...
Phillip Gu, MD, assistant professor at the Widjaja Inflammatory Bowel Disease Institute at Cedar Sinai Medical Center, discusses the baseline characteristics of the case: Editor’s note: The following ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results